GSK's Shingrix Receives the US FDA's Approval to Prevent Shingles in Immunocompromised Adults
Shots:
- The approval is based on studies evaluating the safety & efficacy of Shingrix in adults aged ≥18yrs. who had undergone auHSCT and those undergoing treatment for hematological malignancies (post-hoc analysis)
- The safety & immunogenicity data were generated in adults who were or anticipated to be- immunodeficient/immunosuppressed due to known therapy including patients with HIV- solid tumors- and renal transplants
- Shingrix (IM- 2 doses) is a non-live- recombinant sub-unit adjuvanted vaccine- initially approved for the prevention of shingles in adults aged ≥50yrs. in the US. The approval for this new population expands the number of people who can be protected against shingles
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com